Illumina said after the close of the market recently that it intends to offer approximately $650 million of convertible senior notes due 2023.

Bio-Rad Laboratories reported after the close of the market recently that its second quarter revenues increased 14 percent year over year, driven by growth in both its Life Science and Clinical Diagnostics businesses.

Finnish consumer genetic testing firm Negen has turned to BC Platforms for analysis of raw genomic data for clinical reporting purposes, the companies announced recently.

Recently, leading molecular diagnostic data analysis startup Tempus announced the completion of E round of financing, with a total financing of 110 million dollars.

The Biodesix VeriStrat test received an extra dose of validation last week through a 1,048-patient study published in the Oncologist. The study demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer (NSCLC).

NEW YORK (GenomeWeb) – Shanghai, China-based cancer precision medicine company OrigiMed said today it will collaborate with Illumina to develop oncology assays.

Thermo Fisher Scientific recently reported a 22 percent increase in second-quarter revenues that was partly driven by acquisitions and increased its revenue and earnings guidance for the year for the second time in a row.

Xiamen Spacegen, a provider of oncology molecular diagnostics products and services in China, said recently that it had received CE marking for six testing kits.

The first kit with CE-IVD certification for the molecular diagnostic quantification of Hepatitis delta virus (HDV) RNA is now available, thus reaching an important new milestone in standardization of HDV nucleic acid amplification tests.

November 28, medical apparatus and instruments B2B platform Baden medical announced to get 65 million yuan of A round of financing.

Recently, Siemens medical systems co., LTD. (hereinafter referred to as "Siemens medical China") with us in a big health industry holding co., LTD.

Shares were suspended after three months, thereof in the day evening to disclose the material assets reorganization plan, proposed by issuing shares in combination with cash

Oxford Nanopore Technologies said that it has raised ￡100 million ($126.6 million) in a private placement of ordinary shares.

Recently, minimally invasive Medical science co., LTD. (hereinafter referred to as "minimally invasive medicine") and the United States shares listed Medical devices company Lombard Medical announced that

Menarini - Silicon biosystems company said today that biological systems have yeung sum, Janssen and Johnson & Johnson subsidiary agreement, purchase yeung sum all the Cellsearch circulating tumor cells (CTC)